Tofacitinib use in ulcerative colitis: An expert consensus for day-to-day clinical practice

被引:8
作者
Banerjee, Rupa [1 ]
Sharma, Vishal [2 ]
Patel, Rajendra [1 ]
Jena, Anuraag [3 ]
Pal, Partha [1 ]
Raghunathan, Nalini [1 ]
Kumar, Ajay [4 ]
Sood, Ajit [5 ]
Puri, Amarender S. [6 ]
Goswami, Bhabhadev [7 ]
Desai, Devendra [8 ]
Mekala, Dhanush [1 ]
Ramesh, G. N. [9 ]
Rao, G. V. [1 ]
Peddi, Kiran [10 ]
Philip, Mathew [11 ]
Tandon, Manu [1 ]
Bhatia, Shobna [12 ]
Godbole, Shubhankar [1 ]
Bhatia, Sumit [13 ]
Ghoshal, Uday C. [14 ]
Dutta, Usha [2 ]
Midha, Vandana [5 ]
Prasad, V. G. Mohan [15 ]
Reddy, D. Nageshwar [1 ]
机构
[1] Asian Inst Gastroenterol, Dept Med Gastroenterol, Mindspace Rd, Hyderabad 500032, India
[2] Postgrad Inst Med Educ & Res, Dept Dermatol Venereol & Leprol, Sect 12, Chandigarh 160 012, India
[3] IMS & SUM Hosp, K8 Kalinga Nagar, Bhubaneswar 751003, Odisha, India
[4] BLK MAX Super Special Hosp, Dept Neonatol, Pusa Rd, Delhi 110005, India
[5] Hospital, Dayanand Med Coll, Civil Lines, Ludhiana 141001, India
[6] Medanta Hosp, CH Baktawar Singh Rd,Medicity,Islampur Colony,Sect, Gurugram 122001, India
[7] Dispur Hosp, Gauhati 781005, India
[8] Hinduja Hosp, Mahim West, Mahim, 8-12, Swatantryaveer Savarkar Rd, Mumbai 400028, India
[9] Aster Hosp, Kuttisahib Rd Cheranelloor,South Chittoor, Kochi 682027, India
[10] Yashoda Hosp, 6-3-905 Raj Bhavan Rd, Hyderabad 500082, India
[11] Lisie Hosp, Dept Med Gastroenterol, Lisie Hosp Rd, Ernakulam 682018, India
[12] Natl Inst Med Sci, Kalwad Kalan & Khurd, Jaipur 303121, India
[13] Paras Hosp, Sec-43,Sushant Lok, Gurugram, India
[14] Apollo Multispecialty Hosp, Apollo Inst Gastrosciences & Liver, 58 Canal Circular Rd, Kolkata 700054, India
[15] VGM Hosp, 2100 Trichy Rd, Coimbatore 641005, Tamil Nadu, India
关键词
Herpes zoster; Inflammatory bowel disease; Janus kinase; Tofacitinib; Tuberculosis; Ulcerative colitis; Upadacitinib; INFLAMMATORY-BOWEL-DISEASE; HERPES-ZOSTER; RHEUMATOID-ARTHRITIS; OPPORTUNISTIC INFECTIONS; RISK; TUBERCULOSIS; MANAGEMENT; OUTCOMES; IMMUNE; SAFETY;
D O I
10.1007/s12664-023-01507-9
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Rising number of inflammatory bowel disease (IBD) cases in developing countries necessitate clear guidance for clinicians for the appropriate use of advanced therapies. An expert consensus document was generated to guide the usage of tofacitinib, a Janus kinase inhibitor, in ulcerative colitis. Tofacitinib is a useful agent for the induction and maintenance of remission in ulcerative colitis. It can be used in the setting of biological failure or even steroid-dependent and thiopurine refractory disease. Typically, the induction dose is 10 mg BD orally. Usually, clinical response is evident within eight weeks of therapy. In those with clinical response, the dose can be reduced from 10 mg BD to 5 mg BD. Tofacitinib should be avoided or used cautiously in the elderly, patients with cardiovascular co-morbidity, uncontrolled cardiac risk factors, previous thrombotic episodes and those at high risk for venous thrombosis or previous malignancy. Baseline evaluation should include testing for and management of hepatitis B infection and latent tuberculosis. Where feasible, it is prudent to ensure complete adult vaccination, including Herpes zoster, before starting tofacitinib. The use of tofacitinib may be associated with an increased risk of infections such as herpes zoster and tuberculosis reactivation. Maternal exposure to tofacitinib should be avoided during pre-conception, pregnancy, and lactation. There is emerging evidence of tofacitinib in acute severe colitis, although the exact positioning (first-line with steroids or second-line) is uncertain.
引用
收藏
页码:22 / 35
页数:14
相关论文
共 90 条
[1]   JAK Inhibitors Safety in Ulcerative Colitis: Practical Implications [J].
Agrawal, Manasi ;
Kim, Eun Soo ;
Colombel, Jean-Frederic .
JOURNAL OF CROHNS & COLITIS, 2020, 14 :S755-S760
[2]   Short-term effectiveness and safety of tofacitinib in ulcerative colitis-real world data from tertiary medical centers in Israel [J].
Avni-Biron, Irit ;
Shitrit, Ariella Bar-Gil ;
Koslowsky, Benjamin ;
Levartovsky, Asaf ;
Kopylov, Uri ;
Weisshof, Roni ;
Cohen, Nathaniel Aviv ;
Maharshak, Nitsan ;
Hovel, David ;
Israeli, Eran ;
Naftali, Timna ;
Goren, Idan ;
Snir, Yfat ;
Ollech, Jacob E. ;
Banai-Eran, Hagar ;
Broitman, Yelena ;
Sharar-Fischler, Tali ;
Dotan, Iris ;
Yanai, Henit .
DIGESTIVE AND LIVER DISEASE, 2022, 54 (02) :192-197
[3]   Identifying Care Challenges as Opportunities for Research and Education in Inflammatory Bowel Disease in South Asia [J].
Balasubramaniam, Madhura ;
Nandi, Neilanjan ;
Aswani-Omprakash, Tina ;
Sebastian, Shaji ;
Sharma, Vishal ;
Deepak, Parakkal .
GASTROENTEROLOGY, 2022, 163 (05) :1145-1150
[4]   Small Molecule Drugs in Inflammatory Bowel Diseases [J].
Ben Ghezala, Ines ;
Charkaoui, Maeva ;
Michiels, Christophe ;
Bardou, Marc ;
Luu, Maxime .
PHARMACEUTICALS, 2021, 14 (07)
[5]   Worldwide Management of Inflammatory Bowel Disease During the COVID-19 Pandemic: An International Survey [J].
Bernstein, Charles N. ;
Ng, Siew C. ;
Banerjee, Rupa ;
Steinwurz, Flavio ;
Shen, Bo ;
Carbonnel, Franck ;
Hamid, Saeed ;
Sood, Ajit ;
Yamamoto-Furusho, Jesus K. ;
Griffiths, Anne ;
Benchimol, Eric, I ;
Travis, Simon ;
Lopes, Susana ;
Rubin, David T. ;
Kaplan, Gilaad G. ;
Armstrong, David ;
Gearry, Richard .
INFLAMMATORY BOWEL DISEASES, 2021, 27 (06) :836-847
[6]  
Bernstein CN, 2001, THROMB HAEMOSTASIS, V85, P430
[7]   Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry [J].
Biemans, Vince B. C. ;
Sleutjes, Jasmijn A. M. ;
Vries, Annemarie C. ;
Bodelier, Alexander G. L. ;
Dijkstra, Gerard ;
Oldenburg, Bas ;
Lowenberg, Mark ;
Bodegraven, Adriaan A. ;
van der Meulen-de Jong, Andrea E. ;
Boer, Nanne K. H. ;
Srivastava, Nidhi ;
West, Rachel L. ;
Romkens, Tessa E. H. ;
Horje, Carmen S. Horjus Talabur ;
Jansen, Jeroen M. ;
van der Woude, C. Janneke ;
Hoekstra, Jildou ;
Weersma, Rinse K. ;
van Schaik, Fiona D. M. ;
Hoentjen, Frank ;
Pierik, Marieke J. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (09) :880-888
[8]   Emerging biologics in inflammatory bowel disease [J].
Chan, Heyson Chi-hey ;
Ng, Siew Chien .
JOURNAL OF GASTROENTEROLOGY, 2017, 52 (02) :141-150
[9]   Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry [J].
Chaparro, Maria ;
Garre, Ana ;
Mesonero, Francisco ;
Rodriguez, Cristina ;
Barreiro-de Acosta, Manuel ;
Martinez-Cadilla, Jesus ;
Arroyo, Maria T. ;
Mancenido, Noemi ;
Sierra-Ausin, Monica ;
Vera-Mendoza, Isabel ;
Jose Casanova, Maria ;
Nos, Pilar ;
Gonzalez-Munoza, Carlos ;
Martinez, Teresa ;
Bosca-Watts, Maia ;
Calafat, Margalida ;
Busquets, David ;
Girona, Eva ;
Llao, Jordina ;
Dolores Martin-Arranz, Maria ;
Piqueras, Marta ;
Ramos, Laura ;
Suris, Gerard ;
Bermejo, Fernando ;
Carbajo, Ana Y. ;
Casas-Deza, Diego ;
Fernandez-Clotet, Agnes ;
Garcia, Maria J. ;
Ginard, Daniel ;
Gutierrez-Casbas, Ana ;
Hernandez, Luis ;
Lucendo, Alfredo J. ;
Marquez, Lucia ;
Merino-Ochoa, Olga ;
Rancel, Francisco J. ;
Taxonera, Carlos ;
Lopez Sanroman, Antonio ;
Rubio, Saioa ;
Domenech, Eugeni ;
Gisbert, Javier P. .
JOURNAL OF CROHNS & COLITIS, 2021, 15 (01) :35-42
[10]   Disseminated Tuberculosis in a Patient Treated with Tofacitinib for Ulcerative Colitis [J].
Charpy, Flora ;
Altwegg, Romain ;
Debourdeau, Antoine .
JOURNAL OF CROHNS & COLITIS, 2022, 16 (04) :685-686